March 24, 2022
RFA-HL-23-010 - Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
RFA-HL-23-011 - Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)
RFA-HL-23-012 - Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
RFA-HL-23-013 - Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
RFA-HL-23-014 - Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
NOT-HL-22-015 - Notice of Application Submission and Due Date Changes for RFA-HL-23-010, "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)"
NOT-HL-22-017- Notice of Application Due Date Changes for RFA-HL-23-012, "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)"
NOT-HL-22-018 - Application Due Date Changes for RFA-HL-23-013, "Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)"
NOT-HL-22-019 - Application Due Date Changes for RFA-HL-23-014, "Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33)"
National Heart, Lung, and Blood Institute (NHLBI)
The purpose of this Notice is to alert potential applicants to a change in key dates for RFA-HL-23-011, "Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identidication (R61/R33 - Clinical Trials Not Allowed)". Changes are shown in bold italics below.
Current dates:
| Application Due Dates | Review and Award Cycles | ||||
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| March 21, 2022 | March 21, 2022 | April 18, 2022 | July 1, 2022 | October 1, 2022 | December 1, 2022 |
| July 21, 2022 | July 21, 2022 | August 18, 2022 | November 1, 2022 | January 1, 2023 | April 1, 2023 |
| November 21, 2022 | November 21, 2022 | December 21, 2022 | March 1, 2023 | May 1, 2023 | July 1, 2023 |
| March 21, 2023 | March 21, 2023 | April 18, 2023 | July 1, 2023 | October 1, 2023 | December 1, 2023 |
| July 21, 2023 | July 21, 2023 | August 18, 2023 | November 1, 2023 | January 1, 2024 | April 1, 2024 |
| November 21, 2023 | November 21, 2023 | December 21, 2023 | March 1, 2024 | May 1, 2024 | July 1, 2024 |
| March 21, 2024 | March 21, 2024 | April 18, 2024 | July 1, 2024 | October 1, 2024 | December 1, 2024 |
| July 21, 2024 | July 21, 2024 | August 18, 2024 | November 1, 2024 | January 1, 2025 | April 1, 2025 |
| November 21, 2024 | November 21, 2024 | December 20, 2024 | March 1, 2025 | May 1, 2025 | July 1, 2025 |
Revised dates (in bold italics):
| Application Due Dates | Review and Award Cycles | ||||
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| March 21, 2022 | March 21, 2022 | April 18, 2022 | July 1, 2022 | October 1, 2022 | December 1, 2022 |
| July 21, 2022 | July 21, 2022 | August 18, 2022 | November 1, 2022 | January 1, 2023 | April 1, 2023 |
| November 21, 2022 | November 21, 2022 | December 21, 2022 | March 1, 2023 | May 1, 2023 | July 1, 2023 |
| February 21, 2023 | February 21, 2023 | April 18, 2023 | July 1, 2023 | October 1, 2023 | December 1, 2023 |
| July 21, 2023 | July 21, 2023 | August 18, 2023 | November 1, 2023 | January 1, 2024 | April 1, 2024 |
| November 21, 2023 | November 21, 2023 | December 21, 2023 | March 1, 2024 | May 1, 2024 | July 1, 2024 |
| February 21, 2024 | February 21, 2024 | April 18, 2024 | July 1, 2024 | October 1, 2024 | December 1, 2024 |
| July 22, 2024 | July 22, 2024 | August 19, 2024 | November 1, 2024 | January 1, 2025 | April 1, 2025 |
| November 21, 2024 | November 21, 2024 | December 20, 2024 | March 1, 2025 | May 1, 2025 | July 1, 2025 |
All other aspects of this FOA remain unchanged.
Mike Pieck, Ph.D.
Telephone: 301-827-7986
Email: [email protected]
and Human Services (HHS)
